Last reviewed · How we verify
NCT05888519
Evaluation of Safety and Tolerability of Investigational Ocular Lubricants
NA trial testing FID123300 ocular lubricant in Dry Eye Disease in 47 participants. Completed in 27 September 2023.
27 September 2023
Quick facts
| Lead sponsor | Alcon Research |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 47 |
| Start date | 24 July 2023 |
| Primary completion | 27 September 2023 |
| Estimated completion | 27 September 2023 |
| Sites | 3 locations across Australia |
Drugs / interventions tested
- FID123300 ocular lubricant
- FID123301 ocular lubricant
- FID122505 ocular lubricant
Conditions studied
- Dry Eye Disease — all drugs for Dry Eye Disease →
Sponsor
Alcon Research — full company profile →
Who can join
18 and older, any sex, with Dry Eye Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate investigational ocular lubricants for their safety and tolerability on subjects with mild to moderate dry eye disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05888519
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of FID123300 ocular lubricant
Trials testing the same drug.
- NCT06444516 — Study of Safety and Performance of a Novel Ocular Lubricant in Subjects With Dry Eye Disease · NA · completed
Other recruiting trials for Dry Eye Disease
Currently open trials in the same condition.
- NCT06596733 — Vit-A-Vision® Clinical Investigation · NA · recruiting
- NCT07264517 — Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED). · Phase 2 · recruiting
- NCT07025811 — A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment · Phase 4 · recruiting
- NCT04946721 — 2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHD · recruiting
- NCT06696625 — Transcutaneous Auricular Vagus Nerve Stimulation in Dry Eye · NA · recruiting
Other Alcon Research trials
Trials by the same sponsor.
- NCT06884202 — Evaluation of Delefilcon A Contact Lenses · NA · completed
- NCT06784063 — Visual Performance With Clareon® Vivity® Intraocular Lenses (IOLs) · NA · completed
- NCT06571656 — Evaluation of the Safety and Tolerability of Ocular Lubricants · NA · terminated
- NCT06660290 — A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes · Phase 3 · completed
- NCT06483113 — DAILIES TOTAL1® Soft Contact Lenses - Post-Market Clinical Follow-up Study · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05888519 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Alcon Research
- Last refreshed: 11 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05888519.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing